Get the Stockscreener App
48.94
1.51%
-0.75
Pre-market:
49.87
0.93
+1.90%
Sanofi Adr stock is traded at $48.94, with a volume of 1.55M.
It is down -1.51% in the last 24 hours and down -0.35% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$49.69
Open:
$49.51
24h Volume:
1.55M
Relative Volume:
0.50
Market Cap:
$118.88B
Revenue:
$43.23B
Net Income/Loss:
$6.79B
P/E Ratio:
12.22
EPS:
4.0051
Net Cash Flow:
$9.17B
1W Performance:
-2.18%
1M Performance:
-0.35%
6M Performance:
-1.13%
1Y Performance:
+1.94%
1-Day Range:
$48.91
$49.57
1-Week Range:
$48.91
$50.43
52-Week Range:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
48.94 | 120.70B | 43.23B | 6.79B | 9.17B | 4.0051 |
|
LLY
Lilly Eli Co
|
1,014.49 | 925.06B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
202.48 | 494.70B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
228.71 | 406.92B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.43 | 256.58B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.89 | 253.84B | 63.90B | 19.05B | 13.05B | 7.5596 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
Press Release: Sanofi completes acquisition of Vicebio - GlobeNewswire Inc.
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock? - Finviz
Deutsche Bank Maintains a Buy Rating on Sanofi (SNY) - Finviz
Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria - Finviz
Sanofi Faces Surprise HQ Search As French Authorities Expand Tax Probe - Sahm
Bloom Energy-Aktie: Vorsicht geboten! - Finanztrends
Abbott-Aktie: 21 Milliarden Dollar für neues Wachstum! - Finanztrends
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Sahm
Wasserstoff-Aktien: Bloom Energy kollabiert erneut, Nel ASA gibt nicht auf und Primary Hydrogen meldet Fortschritte! - Finanztrends
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Why Roche Holding Stock Popped Today - Finviz
Novavax Q3 Earnings & Revenues Beat Estimates, '25 Sales View Raised - Finviz
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness - Sahm
UPDATE - GlobeNewswire Inc.
Sanofi ADR earnings beat by $0.72, revenue fell short of estimates - Investing.com Nigeria
Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark - Sahm
Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Sahm
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease - Sahm
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times - Sahm
Sanofi’s AlphaMedix Achieves Key Efficacy Endpoints in Phase 2 Study - The Globe and Mail
Sanofi (SNYNF) Gets a Buy from J.P. Morgan - The Globe and Mail
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
SanofiAmerican Depositary Shares (NQ: SNY - FinancialContent
UBS Reaffirms Their Buy Rating on Sanofi (SNYNF) - The Globe and Mail
Leerink Partners Sticks to Its Buy Rating for Sanofi (SNYNF) - The Globe and Mail
BostInno🗳️ Vote in Inno Madness round two | 💻 UKG announces layoffs - The Business Journals
Sanofi Expands Insulin Savings Program To Cover All US Patients - Sahm
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):